

## LEGVIO (INCLISIRAN) INJECTION ORDERS

**P:** 877.365.5566 | **F:** 855.889.2946

PATIENT INFORMATION: Fax	completed form, insura	nce information, and clinic	al documentation to 855.889.2946
Patient Name:			
Patient Status: New to Therapy Co	ntinuing Therapy	Next Treatment Dat	te:
MEDICAL INFORMATION			
Diagnosis:			
Pure hypercholesterolemia, unspecified	d (ICD-10: E78.00)		
Mixed hyperlipidemia (ICD-10: E78.2)			
Other hyperlipidemia (ICD-10: E78.49)	70.5		
Hyperlipidemia, unspecified (ICD-10: E78.5)			
Heterozygous familial hypercholesterolemia (ICD-10: E78.011)			
☐ Familial hypercholesterolemia, unspecified (ICD-10: E78.019) ☐ Other: ICD-10:			
Other.	ICD-10	<del></del>	
Patient Weight: lbs. (required)	Allergies:		
THERAPY ORDER			
Leqvio (inclisiran) - choose one:			
enous one.			
$\square$ 284mg subcutaneously initially, at 3 months, and then every 6 months (initial start) x 1 year			
_			
284mg subcutaneously every 6 months x 1 year			
	_		
Lab Orders:	L	.ab Frequency:	
Required labs to be drawn by: $\square$ Par	agon 🛮 Referrin	a Provider	
		<b>9</b>	
Other orders:			
DROVIDED INFORMATION			
PROVIDER INFORMATION  By signing this form and utilizing our services, you are authorizing Pai	ragon Healthcare. Inc. and its em	plovees to serve as your prior auth	orization and specialty pharmacy designated
agent in dealing with medical and prescription insurance companies a	and to select the preferred site of	f care for the patient	
Provider NamePhone:	Signature Fax:	Contact	Date Person:
Provider Name: Signature: Date: Provider NPI: Phone: Fax: Contact Person:  Opt out of Paragon selecting site of care (if checked, please list site of care):			
PREFERRED LOCATION			
			0,70
City: State:	View	our locations here:	

PARAGONHEALTHCARE.COM

IMPORTANT NOTICE: This fax is intended to be delivered only to the named address and contains material that is confidential, privileged property, or exempt from disclosure under applicable law. If you are not the named addressee, you should not disseminate, distribute, or copy this fax. Please notify the sender immediately and destroy all copies if you have received this document in error.





## COMPREHENSIVE SUPPORT FOR LEQVIO (INCLISIRAN) THERAPY

PATIENT INFORMATION:
Patient Name: DOB:
REQUIRED DOCUMENTATION FOR REFERRAL PROCESSING & INSURANCE APPROVAL
$\square$ Include <u>signed</u> and <u>completed</u> order (MD/prescriber to complete page 1)
☐ Include patient demographic information and insurance information
☐ Include patient's current medication list
☐ Supporting clinical notes to include any past tried and/or failed therapies, intolerance, benefits, or contraindications to conventional therapy
☐ Heterozygous familial hypercholesterolemia (HeFH) - Does the patient have a <u>untreated</u> LDL ≥ 190mg/dL (≥ 155mg/dL if <16 years of age)? ☐ Yes ☐ No
Please mark any of the following criteria the HeFH patient meets:
$\square$ Presence of tendon xanthoma(s) in the patient or 1st/2nd degree relative
☐ Family history of MI at <60 years old in 1 <sup>st</sup> degree relative or <50 years old in 2 <sup>nd</sup> degree relative
$\square$ Family history of total cholesterol > than 290mg/dL in a 1st/2nd degree relative
☐ Arcus cornealis before age 45
□ ASCVD - Does the patient's LDL remain ≥ 100mg/dL despite treatment with a high-intensity statin? □ Yes □ No
$\square$ Has the patient tried and failed PCSK9 inhibitor after 12 weeks of use? $\square$ Yes $\square$ No
☐ Has the patient tried and failed a high intensity statin for ≥ 8 continuous weeks? ☐ Yes ☐ No
<ul> <li>□ Indicate any conditions the patient has:</li> <li>□ Acute coronary syndrome</li> <li>□ History of myocardial infarction</li> <li>□ Coronary or other arterial revascularization</li> <li>□ Transient ischemic attack</li> <li>□ Peripheral arterial disease presumed to be of atherosclerotic origin</li> </ul>
☐ Include labs and/or test results to support diagnosis
☐ LDL-C (required)
☐ Mutation in LDL, apoB, or PCSK9 gene (if applicable)
☐ Other medical necessity:

Paragon Healthcare will complete insurance verification and submit all required documentation for approval to the patient's insurance company for eligibility. Our team will notify you if any additional information is required. We will review financial responsibility with the patient and refer him/her to any available co-pay assistance as needed. Thank you for the referral.

Please fax all information to (855) 889-2946 or call (877) 365-5566 for assistance